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Current Management of Advanced and Metastatic 
Renal Cell Carcinoma
M Hammad Ather,1 Nehal Masood,2 Tahmeena Siddiqui3
Introduction: Unresectable renal cell carcinoma (RCC) is a technically 
incurable condition. Historically, RCC is resistant to chemotherapy and 
radiotherapy. Cytokine therapy was until recently considered the mainstay of 
treatment. However, responses are modest. Improvement in the understanding 
of the biology of RCC, particularly the hereditary types, is providing the 
basis for novel therapeutic targets. Our aim was to review the clinical utility 
of various systemic agents and surgery in the management of advanced RCC 
and suggest practice guidelines in the light of current literature.
Materials and Methods: Evidence was collected by review of current 
literature, guidelines of the American and European associations and the 
national comprehensive cancer network.
Results: Treatment of advanced RCC has recently undergone a major 
change with the development of targeted agents and potent angiogenesis 
inhibitors. Small-molecule multikinase inhibitors that target vascular 
endothelial growth factor receptors have a favorable toxicity profile and can 
prolong time to progression and preserve quality of life when used in newly 
diagnosed or previously treated patients; bevacizumab enhances the response 
rate and prolongs disease control when added to interferon-α. Temsirolimus, 
a mammalian target of rapamycin inhibitor, prolongs the survival duration 
of patients with poor-risk disease. All currently available agents have variable 
toxicity profile and they, at best, improve survival by a few months. Surgery 
still has a significant role in the management of stage IV RCC. 
Conclusion: Supportive care and surgery remain the mainstay of treatment 
even in the management of advanced and metastatic RCC. Systemic 
therapeutic agents are showing promising results.
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INTRODUCTION
The current estimate of renal cancer 
incidence is about 200 000 cases, 
making it the 3rd most common 
urogenital cancer worldwide.(1) In 
the United States, an estimated 
51 190 patients were diagnosed 
with renal cell carcinoma (RCC) 
in 2007, and 12 890 would die of 
the disease. (1) Renal cell carcinoma 
comprises a histologically diverse 
group of solid tumors, together 
making up about 3% of all adult 
neoplasms. (1) About one-third of 
patients have metastatic disease at 
presentation, a median survival 
of 7 to 11 months, and a 5-year 
survival of 10%. Its incidence has 
been increasing, a phenomenon 
for which wider use of imaging 
procedures alone cannot account.(2)
Renal cell carcinoma, if detected 
early, is potentially curable by 
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surgery; however, about one-third present with 
metastases and one-third of organ-confined 
cancers treated by nephrectomy develop 
metastases during the follow-up.(3) If surgical 
extirpation alone for all tumor deposits is 
not possible, tumor nephrectomy remains a 
palliative therapy, considered for symptomatic 
control and as part of multimodality treatment 
(eg, in conjunction with immunotherapy or 
experimental therapies). Metastatic RCC is a 
difficult disease to manage, as it is resistant to 
chemotherapy and radiotherapy. Patients with 
metastatic disease have a median survival time of 
less than 12 months. However, survival can be 
quite variable, depending on several prognostic 
factors, including performance status; lactate 
dehydrogenase (LDH), hemoglobin, and calcium 
levels; and the absence of prior nephrectomy.(4)
Recent advances in immunotherapy protocols, 
development of targeted therapy with small-
molecule kinase signal transduction inhibitors, 
vascular endothelial antibodies, and combination 
treatment modalities have shown promising 
trends. Rising incidence, improved imaging and 
other diagnostic procedures, and emerging role 
of multimodality therapeutic concepts justify the 
need for evidence-based guidelines for treatment 
of RCC. Particularly, the challenging aspect is the 
management of locally advanced and metastatic 
RCC. In the current review, we have tried to 
define patient selection, efficacy, and safety of 
some of the newer agents in the light of best 
evidence in the current literature. 
PATHOgENIC PATHWAY 
Renal cell carcinoma exists in 4 distinct 
histological subtypes. These include clear cell, 
papillary, chromophobe, and collecting duct 
tumors. The majority of cases (75%) are clear-cell 
RCC. These are characteristically associated with 
loss of function of the von Hippel-Lindau (VHL) 
gene. Latif and associates(5) reported in a study of 
221 VHL kindred a linkage analysis to identify 
the VHL gene on the short arm of chromosome 
3p. The VHL gene product forms a complex with 
elongin C and B, which further binds to cul-2. 
This results in upregulation of the α-fragment of 
hypoxia inducible factor (HIF) subunits, HIF-
1 and HIF-2.(6) The HIF activation results in 
upregulation of HIF target genes, such as vascular 
endothelial growth factor (VEGF), transforming 
growth factor, hepatocyte growth factor receptor 
(MET), stromal cell-derived factor-1, and others. (7) 
The HIF plays an important role in RCC 
oncogenesis, but besides HIF deregulation, there 
are many other mechanisms and HIF alone is 
probably not sufficient to cause oncogenesis.(8) 
A different histological subtype of RCC, ie, 
papillary type, is not associated with VHL gene at 
3p, but with MET proto-oncogene at chromosome 
7q31. The MET gene encodes a cell membrane 
receptor specific for hepatocyte growth factor. 
Studies have indicated that hepatocyte growth 
factor stimulation leads to mitogenesis, cellular 
migration, and morphogenesis.(9)
PROgNOSTIC INDICATORS
Renal cell carcinoma is a heterogeneous disease 
that is recognized based on differences in 
morphology, genetic alterations, and clinical 
behavior. In view of variable biological behavior 
and poor results of most therapies for advanced 
and metastatic RCC, it is important to have 
a universally acceptable prognostic model. 
Currently, some pathological factors are 
not covered by the TNM classification. The 
nonpathological factors such as performance 
status, thrombocytosis, and neutrophilia are 
also important. The predictors of short survival 
include serum LDH levels higher than 1.5 times 
upper limit of normal, low hemoglobin levels, 
corrected serum calcium levels higher than 
10 mg/dL (2.5 mmol/L), a time interval of less 
than 1 year from original diagnosis to the start 
of systemic therapy, the Karnofsky performance 
score of 70 or lower, and 2 or more sites of organ 
metastases.(10)
Angiogenesis is a critical step in the growth, 
invasive progression, and metastatic spread of 
solid tumors. Recently, Minardi and coworkers(11) 
assessed the importance of tumor necrosis, 
microvessel density, vascular endothelial growth 
factor (VEGF), and HIF-1α immunohistochemical 
expression in a large series of clear-cell RCCs 
treated with radical nephrectomy and assessed 
the prognostic value of their expression in terms 
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of patient survival in long-term follow-up. They 
noted that tumor necrosis, microvascular invasion 
and renal capsular infiltration are more likely 
to occur in higher stages and grades of RCC; 
cytoplasmic HIF-1α is highly expressed in high-
grade RCC. Survival is dependent upon tumor 
stage and grade, the presence of vascular invasion 
and capsular infiltration, and tumor necrosis. 
Microvessel density also resulted as being an 
important prognostic factor. Generally, VEGF 
and HIF-1α correlate with prognosis in high-
stage tumors and VEGF is the most important 
independent prognostic factor for cancer-specific 
death. The histological and immunohistochemical 
parameters considered here can influence disease 
recurrence and survival in RCC. 
TREATMENT
Role of Surgery in Management of 
Advanced and Metastatic Renal Cell 
Carcinoma
Surgery has a significant role in the overall 
management of advanced RCC (Figure). 
Regional lymph node involvement on imaging 
may be reactive or hyperplastic only; therefore, 
surgical resection and pathological evaluation 
become important. In a recent report, Margulis 
and coworkers(12) noted that true pathologic 
involvement of adjacent organs by RCC cannot 
be predicted from pre-operative or intra-
operative parameters. A significant proportion 
of patients clinically suspected of having T4 
RCC are downstaged and benefit from aggressive 
surgical resection with en bloc removal of the 
involved organs. Moshrafa and associates(13) 
demonstrated that radical nephrectomy in the 
setting of metastatic RCC has a low morbidity 
and acceptable recovery in these patients 
with advanced primary tumors and poorer 
performance status. Patients with primary renal 
tumor and isolated metastatic site or with isolated 
metastatic recurrence benefit from surgical 
extirpation.(14) Complete resection of either 
synchronous or metachronous solitary metastases 
from RCC is justified and can contribute to 
a long-term survival in this selected group of 
patients. 
Nephrectomy in patients with advanced RCC 
prior to the introduction of effective systemic 
therapy was a palliative procedure without 
significant improvement in overall survival. 
With the introduction of immunotherapy, and 
more recently, molecularly targeted therapy, 
nephrectomy has shown to improve survival 
when performed before interferon (IFN) therapy 
in a selected group of patients. There is, however, 
lack of high level of evidence as to whether to 
remove the primary tumor prior to the targeted 
therapy or following it up. The initiation of a 
phase 3 study should be considered to compare 
the survival of patients treated by nephrectomy 
plus targeted therapy with the survival of 
patients treated by targeted therapy alone, with 
nephrectomy reserved for clinical indications, in 
order to answer these questions. Until evidence 
Management algorithm of locally advanced and metastatic renal cancer (stage IV). 
*The National Comprehensive Cancer Network practice guidelines for kidney cancer. 2008. Available from: http://www.nccn.org
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from such a study becomes available to guide 
physicians, and without evidence to the contrary, 
cytoreductive nephrectomy should be considered, 
as it has shown a survival benefit, and should 
be used in appropriately selected patients with 
metastatic RCC receiving postsurgical systemic 
therapies.(15) The Southwest Oncology Group trial 
on 8949 patients and the European Organization 
for the Research and Treatment of Cancer trial 
on 30 947 are two remarkable studies on the 
issue.(16-18) Using an identical treatment protocol 
(designed by the former group), these trials 
provide the best information to date regarding 
the use of cytoreductive nephrectomy. Both trials 
demonstrated significantly longer overall survival 
in the groups randomized to nephrectomy before 
immunotherapy, and this benefit persisted across 
all study stratifications, including performance 
status, site of metastasis, and measurable versus 
nonmeasurable disease.
Immunotherapy for Metastatic Renal Cell 
Carcinoma
Renal cell carcinoma evokes immune response 
that occasionally results in spontaneous tumor 
regression.(19) Spontaneous regression of 
metastatic RCC is a rare but well-documented 
event, most often involving pulmonary 
metastases; however, its incidence is about 
0.1%. (23) Over the past several decades, in order 
to duplicate, an accentuated response of various 
immunomodulations have been attempted. These 
include specific and nonspecific stimulation of 
the immune system. Most of these therapies 
have shown antitumor activity; however, the 
most consistent results have been observed only 
with interleukin-2 (IL-2) and with IFN-α. These 
agents target various inherent immune defects in 
RCC. Particularly important are the qualitative 
and quantitative defects in dendritic cell function 
in RCC,(20) which result in inherent immune 
deficiency and tumor progression. Renal cell 
carcinoma also alters body’s antitumor immunity 
by altering the T-cell function in cytokine 
production by T helper cells.(21) 
Interferon-α Trials. Interferon-α is a glycoprotein 
produced in response to viral infections and 
foreign antigens. The postulated mechanisms 
of action in RCC include immunomodulation, 
antiproliferative, and anti-angiogenic activities. 
Interferon-α is produced by macrophages and 
lymphocytes and induces several biological effects 
including immunomodulation, antiproliferation, 
and enhanced expression of cell surface antigens. 
In phase 2 studies, recombinant IFN- α is reported 
to induce response to treatment of RCC in up to 
29% of cases.(22) In a randomized controlled trial 
by the Medical Research Council renal cancer 
collaboration,(23) 335 patients were randomized 
into two groups to receive either IFN-α or 
medroxyprogesterone. In this intention-to-treat 
analysis, there was a significant advantage in 
overall survival for patients treated with IFN-α 
(P = .02). The median survival was 2.5 months 
more in this group. In another trial, 160 patients 
were randomized to receive a chemotherapeutic 
agent, vinblastine, or IFN-α versus vinblastine 
alone.(24) The authors noted a significant overall 
survival advantage of 7 months (P = .005) in the 
IFN-α arm. There was also a significant difference 
in the overall response rate (16.5% versus 2.4%; 
P = .003), complete response rate (8.9% versus 
1.2%), and median time to disease progression (3 
months versus 2 months; P < .001), all favoring 
IFN-α. Coppin and colleagues(25) performed 
a meta-analysis of 53 randomized controlled 
trials with over 6000 patients treated over a 
decade between 1995 and 2004. They noted that 
compared to control patients, those who received 
IFN-α had a 3.8 months of median improvement 
in survival (P = .007).
Interestingly, IFN-α, in spite of being one of the 
most commonly used agents until recently and 
often adopted as the control arm in comparative 
trials with new drugs, has never been approved in 
the United States for treatment of RCC.
Interleukin-2 Trials. Interleukin-2, a 
glycoprotein, produced in response to infections, 
is important in identifying self and foreign 
antigens. The antitumor action of IL-2 is not 
completely understood; however, it is postulated 
to have direct killing action by activated T cells 
and natural killer cells.(26)
Various modes of delivery for IL-2, including 
intravenous and subcutaneous, have also been 
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studied, attempting to maximize efficacy and 
decrease the significant toxicities that can be 
associated with high-dose IL-2 therapy. The 
importance of dose intensity of IL-2 for patients 
with metastatic RCC was clarified in a National 
Institutes of Health trial that randomized patients 
to receive high-dose IL-2 (156 patients) or a dose 
that was 10 times lower (150 patients). There was 
a significantly higher response rate with high-dose 
IL-2 than with low-dose intravenous IL-2 (21% 
versus 13%), but no overall survival difference, 
and a higher morbidity, as anticipated.(27) This 
was confirmed in a multi-institutional phase 3 
trial involving 192 patients with metastatic RCC 
randomized to receive intravenous high-dose IL-2 
or subcutaneous low-dose IL-2 plus IFN-α. The 
response rate was significantly greater in patients 
treated with high-dose IL-2 (23.2% versus 9.9%). 
While there was no significant difference in 
overall survival (17 months versus 13 months), 7% 
of the patients were reported alive and disease free 
after 3 years of follow-up in the high-dose IL-2 
arm versus none in the control arm. As expected, 
there were more grade 3 and 4 toxicities in the 
high-dose IL-2 arm, although treatment-related 
mortality was rare.(28) The authors concluded 
that high-dose IL-2 was an acceptable therapy 
for patients with little or no comorbidities and 
excellent performance status, for whom the 
possibility of long-term complete response is 
worth the complexity, risk, and acute toxicity of 
the treatment. How to best sequence or combine 
IL-2 with newer drugs is unknown. 
Overall, in most reported series, toxicity is 
worse with IL-2-based therapy than with non-
IL-2 therapy; however, most studies described 
IL-2 regimens as moderately to well tolerated by 
most patients.(22) Specific to IL-2, hypotension, 
cardiac toxicity, diarrhea, and fatigue increased 
when compared with IFN-α or other treatment 
arms. None of the trials studied in the meta-
analysis by Hotte and colleagues(29) reported toxic 
deaths or quality-of-life changes. It is, however, 
important to understand that IL-2-based regimens 
are associated with significant toxicity, and the 
magnitude of this toxicity may be underestimated 
in clinical trials because of patient selection 
factors. Specialized centers have the expertise 
to manage and minimize the impact of these 
toxicities.
In a meta-analysis of trials on IL-2 versus non-
IL-2,(29) Hotte and colleagues noted that the 
response rates were higher in patients receiving 
IL-2-based regimens (range, 6.5% to 39%), 
compared with non-IL-2 controls (zero to 20%). 
All 6 trials that they included in their analysis 
reported mortality data, and when the 6 trials 
were pooled in a meta-analysis, mortality at 1 
year was not significantly different between IL-
2-based regimens and non-IL-2 regimens. Hotte 
and colleagues(29) concluded that non-high-dose 
IL-2 containing regimens do not provide superior 
treatment efficacy over non-IL-2-based regimens, 
with added toxicity, and therefore, should not 
be used as standard treatment for patients with 
unresectable or metastatic RCC. Rosenberg(30) 
showed that IL-2 is the only systemic treatment 
currently available that is capable of curing 
patients with metastatic RCC, albeit in smaller 
number of patients with unmaintained complete 
response. 
Multikinase Inhibitors 
Deregulation of HIF is an important aspect of 
RCC development. Thus, agents that affect HIF 
target genes, especially those encoding VEGF 
and VEGF receptors, may be particularly useful. 
Small-molecule kinase inhibitors that have more 
than one target (multikinase inhibitors) like 
sorafenib and sunitinib malate are being currently 
evaluated in many clinical trials. These agents 
have potent activities against specific kinases; 
however, the true biologic targets responsible for 
tumor regression are not precisely known.
The ability of solid tumors to invade and develop 
metastasis depends on angiogenesis. Targeted 
therapies, like multikinase inhibitors and anti-
angiogenic antibodies, reduce tumor vascularity 
and induce tumor necrosis before a change in 
tumor size or volume is observed.(31) Standard 
response end points based on unidimensional 
and bidimensional measurements, such as the 
Response Evaluation Criteria in Solid Tumors 
or the World Health Organization criteria, 
originally designed to evaluate cytotoxic drugs, do 
not accurately reflect changes in tumor volume, 
and therefore, often fail to accurately register 
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responses to targeted agents, which are typically 
cytostatics.(32) Imaging techniques that provide 
morphologic and functional perfusion data, such 
as Doppler ultrasonography with contrast agent 
injection,(23) may be combined with standard 
criteria to better assess the efficacy of targeted 
agents. 
Sunitinib. Sunitinib malate is an orally 
administered inhibitor of a number of tyrosine 
kinases, including VEGF receptor and the 
platelet-derived growth factor receptor,(33) which 
are known to play a significant role in the 
pathogenesis of RCC through their involvement 
with the VHL gene. A recently published phase 3 
randomized trial(34) reported the superior efficacy 
of sunitinib malate over IFN for patients with 
locally advanced unresectable or metastatic RCC 
who had had no previous systemic therapy. These 
results were based on the pooled analysis of 2 
phase 2 studies of sunitinib for patients who had 
undergone previous cytokine therapy and had a 
response rate of 42%.(35)
In a phase 3 study,(36) using IFN as a control 
for advanced RCC, 750 patients with clear cell 
histology without prior systemic therapy were 
randomized to receive either sunitinib or IFN. 
None of the patients had complete response, 
partial responses were observed for 31% of 
patients treated with sunitinib and 6% of those 
treated with IFN. The median progression-
free survival was 11 months for patients in the 
sunitinib arm and 4 months for those in the 
IFN arm (hazards ratio, 0.42; 95% confidence 
interval, 0.33 to 0.52). All differences were highly 
significant. Subgroup analyses suggested that 
patients with various risk factors seemed to have 
similar benefits with sunitinib. When divided 
into good-, intermediate-, or poor-risk categories 
according to the Motzer criteria, patients in all 
the three categories that received sunitinib fared 
better than those who received IFN.(25) Although 
few patients were categorized in the poor-risk 
group (23 patients in the sunitinib group and 
25 in the IFN group), the trend was toward 
improvement in median progression-free survival 
(4 months versus 1 month, respectively; hazards 
ratio, 0.53; 95% confidence interval, 0.23 to 1.23). 
Health-related quality of life measured in this 
study was better in the sunitinib group than in 
the IFN group (P < .001). The results of this 
large phase 3 trial convincingly demonstrated that 
sunitinib was significantly better than IFN for 
previously untreated patients with advanced RCC 
and should be considered the new standard of care 
for first-line treatment of this disease. 
Diarrhea and fatigue were the most commonly 
reported treatment-related adverse events of 
sunitinib, and other adverse events included 
stomatitis, hand-foot syndrome (characterized 
by painful lesions on the palms and soles), and 
hypertension.(37) Neutropenia was reported, 
but there were no reports of associated fever 
or sepsis. (35) Elevated serum concentrations of 
lipase were not associated with clinical signs or 
symptoms of pancreatitis.(37)
Sorafenib. Sorafenib is an orally administered 
multikinase inhibitor that targets Raf kinase 
and receptor tyrosine kinases, including VEGF 
receptor-2 and platelet-derived growth factor 
receptor-β.(36) Sorafenib’s antitumor activity is 
by targeting the tumor or tumor endothelium 
to inhibit proliferation and angiogenesis.(38,39) In 
phase 2/3 trials, sorafenib significantly prolonged 
progression-free survival versus placebo and 
showed good tolerability in advanced RCC 
patients.(37) Based on these phase 2/3 RCC trial 
findings, sorafenib was approved recently for 
the treatment of advanced RCC. Sorafenib may 
be acting through inhibition of angiogenesis in 
RCC, but the precise mechanism of action by 
which sorafenib exerts its clinical effects, and the 
etiologic role of the Raf/MEK/ERK pathway, is 
undergoing further investigation in this tumor 
type.
In the Treatment Approaches in Renal Cancer 
Global Evaluation Trial, 903 previously treated 
patients with metastatic clear-cell RCC of low 
or intermediate risk, according to the Memorial 
Sloan-Kettering Cancer Center classification,(39) 
were randomized to receive sorafenib or placebo. 
The median progression-free survival times were 
5.5 months in the sorafenib group and 2.8 months 
in the placebo group, and the objective response 
rates were 10% in the sorafenib arm and 2% in the 
placebo arm. Although the difference in survival 
favoring sorafenib was not significant, it may have 
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been because of early crossover allowed shortly 
after an interim analysis showed a difference 
in progression-free survival. Discontinuation 
of treatment because of side effects occurred in 
10% of patients receiving sorafenib, and 13% 
required dose reductions because of toxicity. The 
most important side effects were diarrhea (43%), 
hypertension (17%), skin rash (40%), and hand-
foot syndrome (30%).(40)
Unlike the results for sunitinib, results for 
sorafenib do not justify its use as adjuvant in 
patients at high risk of recurrence following 
nephrectomy. Potential patients should be 
referred to centers participating in such trials.
Anti-angiogenic Therapy in Metastatic 
Renal Cell Carcinoma
The majority of RCCs have upregulation of the 
HIF and the resultant upregulation of target gene 
VEGF. Bevacizumab is a humanized recombinant 
anti-VEGF antibody that binds all types of 
VEGF-A isoforms.(41) Bevacizumab was tested 
in a phase 2 trial of 116 patients with metastatic 
clear-cell RCC who were randomized to receive 
placebo or low-dose (3 mg/kg) or high-dose (10 
mg/kg) bevacizumab, given every 2 weeks. There 
was a 10% objective partial response rate, which 
was confined to the high-dose arm. Compared 
with placebo, there was also a significantly longer 
time to disease progression (4.8 months versus 2.5 
months).(42)
Most recently, a phase 3 trial involving 641 
patients with metastatic clear-cell RCC compared 
IFN-α combined with either bevacizumab 
or placebo. When compared with placebo, 
bevacizumab resulted in a significantly longer 
progression-free survival (10.2 months versus 5.4 
months) and higher objective tumor response rate 
(30.6% versus 12.4%). In an interim analysis, there 
was no significant survival advantage. Common 
toxicities seen in this and previous trials were 
hypertension, proteinuria, and a tendency to 
bleeding and thrombotic events.(43)
CONCLUSION
The grade of recommendation for the 
abovementioned treatment option is listed in the 
Table. Surgery still plays a significant role in the 
management of advanced and metastatic RCC. 
In a selected group of patients, resection of the 
primary tumor along with complete resection 
of solitary or limited metastases can lead to 
long-term disease-free or relapse-free survival. 
Nephrectomy before immunotherapy has been 
shown in phase 3 trials to result in a survival 
benefit in patients with good performance status 
and limited burden of disease, although the overall 
improvement in survival is modest. In patients 
with nonresectable disease or those with residual 
disease following maximal surgical extirpation, 
the systemic therapy with immunological agents 
and targeted therapy remain a viable option. 
Recent reports have indicated encouraging 
results with these agents. Sorafenib, sunitinib 
and temsirolimus have all been shown to 
significantly alter the natural history of advanced 
RCC, and many more agents are currently being 
evaluated. Trials evaluating combinations of 
these agents are currently underway or planned, 
and the optimal sequence of use of these agents 
is also being evaluated. However, much more 
evidence is necessary before the utility of these 
novel inhibitors of angiogenesis is established in 
providing the ultimate clinical benefit to patients 
diagnosed with RCC. In a recently reported phase 
Intervention Grade of Recommendation
Tumor nephrectomy + interferon-α* A
Metastasectomy (synchronous and metachronous)*† B
Radiotherapy B
Chemotherapy (5-fluorouracil) + immunotherapy B
Immunotherapy (control arm in trials, interferon-α + interleukin-2 for clear-cell histology) A
Tyrosine kinase inhibitors (sorafenib as 2nd line, sunitinib as 1st line*, temsirolimus 1st line‡) A
grade Of Evidence in the Management of Metastatic Renal Cell Carcinoma
*good performance status.
†Surgically resectable, metastasectomy in patients with residual disease should be performed in patients with resectable lesion previously 
responding to immunotherapy. This option has been recommended for osseous and brain lesions.
‡Poor-risk patients.
Advanced and Metastatic Renal Cell Carcinoma—Ather et al
8 Urology Journal    Vol 7    No 1    Winter 2010
3, randomized, double-blind, placebo-controlled 
trial by Motzer and colleagues(44) the role of 
everolimus in patients with metastatic RCC 
was assessed. They noted that treatment with 
everolimus prolongs progression-free survival 
relative to placebo in patients with metastatic 
renal cell carcinoma that had progressed on 
other targeted therapies. The available agents for 
advanced RCC are toxic but can prolong life for a 
couple of months. 
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